Sugi Predict

Sugi Predict / Compounds / SCHEMBL18854324

SCHEMBL18854324

SCHEMBL18854324

CC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ ERAP2 Q6P179 3/20 0.58
▸ NPBWR1 P48145 15/20 0.54
▸ IL1RN P18510 2/20 0.54
▸ ERAP1 Q9NZ08 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18862075 0.94 NPBWR1 (0.60) ERAP2NPBWR1
SCHEMBL18854333 0.94 ERAP2 (0.57) ERAP2NPBWR1IL1RNERAP1
SCHEMBL18862079 0.90 GHSR (0.62) —
SCHEMBL31256796 0.89 NPBWR1 (0.59) NPBWR1
SCHEMBL30376277 0.88 NPBWR1 (0.60) NPBWR1
SCHEMBL38652462 0.87 ERAP2 (0.64) ERAP2IL1RNERAP1
SCHEMBL31583852 0.86 ERAP2 (0.63) ERAP2IL1RNERAP1
SCHEMBL29378588 0.86 ERAP2 (0.63) ERAP2IL1RNERAP1
SCHEMBL31004384 0.86 ERAP2 (0.61) ERAP2IL1RNERAP1
SCHEMBL29531497 0.86 ERAP2 (0.61) ERAP2IL1RNERAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851367-B2 Tissue-specific genome engineering using CRISPR-Cas9 PFIZER INC. (US) 2020-12-01 — — US disclosed
US-20170137801-A1 TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-05-18 — — US disclosed
US-20170137801-A1 TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2017-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851367-B2 Tissue-specific genome engineering using CRISPR-Cas9 ASGR1, LDLR, HAVCR2 ERAP2 411/4885NPBWR1 1332/4885IL1RN 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback